Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Robert F. Hoedemaeker"'
Autor:
Florus C. de Jong, Teemu D. Laajala, Robert F. Hoedemaeker, Kimberley R. Jordan, Angelique C. J. van der Made, Egbert R. Boevé, Deric K. E. van der Schoot, Bart Nieuwkamer, Emiel A. M. Janssen, Tokameh Mahmoudi, Joost L. Boormans, Dan Theodorescu, James C. Costello, Tahlita C. M. Zuiverloon
Publikováno v:
Science Translational Medicine, 15(697):eabn4118. American Association for the Advancement of Science
The recommended treatment for patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) bladder instillations. However, only 50% of patients benefit from this thera
Autor:
Florus C. de Jong, Teemu D. Laajala, Robert F. Hoedemaeker, Sébastien Rinaldetti, Kimberley R. Jordan, Angelique C.J. van der Made, Bart Nieuwkamer, Deric K.E. van der Schoot, Egbert R. Boevé, Emiel A.M. Janssen, Tokameh Mahmoudi, Joost L. Boormans, Dan Theodorescu, James C. Costello, Tahlita C.M. Zuiverloon
Publikováno v:
Journal of Urology. 207
Autor:
Jolien T. M. Mensink, Ellen C. Zwarthoff, Tahlita C.M. Zuiverloon, Joep J. de Jong, Vebjørn Kvikstad, Deric K. Van der Schoot, Florus C. de Jong, Joost L. Boormans, Robert F. Hoedemaeker, Egbert R. Boevé
Publikováno v:
Journal of Urology, 205(3), 701-708. Elsevier Inc.
Journal of Urology
Journal of Urology
PURPOSE: Currently, markers are lacking that can identify patients with high risk nonmuscle invasive bladder cancer who will fail bacillus Calmette-Guérin treatment. Therefore, we evaluated the prognostic value of T1 substaging in patients with prim
Autor:
Michael A. den Bakker, Natascha N T Goemaere, Robert F. Hoedemaeker, Mike Kliffen, Eva Hollemans, Margaretha A van der Slot, Geert J.L.H. van Leenders, Leo M. Budel
Publikováno v:
Virchows Archiv, 478(2), 249-256. Springer-Verlag
The Grade group is an important parameter for clinical decision-making in prostate cancer. Recently, percent Gleason pattern 4 and presence of invasive cribriform and/or intraductal carcinoma (CR/IDC) have been recognized for their independent predic
Autor:
Florus C. de Jong, Teemu D. Laajala, Robert F. Hoedemaeker, Kimberley R. Jordan, Angelique C.J. van der Made, Egbert R. Boevé, Deric K.E. van der Schoot, Bart Nieuwkamer, Emiel A.M. Janssen, Tokameh Mahmoudi, Joost L. Boormans, Dan Theodorescu, James C. Costello, Tahlita C.M. Zuiverloon
SummaryThe recommended treatment for patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) bladder instillations. However, only 50% of patients benefit from this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7861d07c69b6687a36a8d6eba9e2a430
https://doi.org/10.1101/2021.11.30.21266988
https://doi.org/10.1101/2021.11.30.21266988
Autor:
Tahlita C.M. Zuiverloon, Sébastien Rinaldetti, Ellen C. Zwarthoff, James C. Costello, Joep J. de Jong, Dan Theodorescu, Robert F. Hoedemaeker, Teemu D. Laajala, Angelique C. van der Made, Egbert R. Boevé, Florus C. de Jong, Jolien T. M. Mensink, Joost L. Boormans, Deric K. Van der Schoot
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Intravesical Bacillus Calmette-Guerin (BCG) is the recommended treatment option in high-risk non-muscle invasive bladder cancer (HR-NMIBC). However, disease recurrence oc...
Autor:
D.K.E. Schoot, Teemu D. Laajala, Ellen C. Zwarthoff, Joost L. Boormans, F.C. De Jong, James C. Costello, Sébastien Rinaldetti, A.C.J. Van Der Made, Egbert R. Boevé, Tahlita C.M. Zuiverloon, Dan Theodorescu, Robert F. Hoedemaeker, Jolien T. M. Mensink
Publikováno v:
European Urology. 79:S612-S613
Autor:
Joost L. Boormans, Sébastien Rinaldetti, E.C. Zwarthoff, Florus C. de Jong, Deric K. Van der Schoot, Jolien T. M. Mensink, Dan Theodorescu, Teemu D. Laajala, Angelique C. van der Made, Egbert R. Boevé, Robert F. Hoedemaeker, James C. Costello, Tahlita C.M. Zuiverloon
Publikováno v:
Cancer Research. 81:614-614
Intravesical instillations with Bacillus Calmette-Guérin (BCG) are the recommended treatment in T1 high-grade (HG) bladder cancer (BC) patients. However, even with BCG treatment, 50% of patients develop a HG recurrence or progression to advanced dis
Autor:
Teemu D. Laajala, Sébastien Rinaldetti, Robert F. Hoedemaeker, Deric K. Van der Schoot, Angelique C. van der Made, Tahlita C.M. Zuiverloon, Florus C. de Jong, Joost L. Boormans, Egbert R. Boevé, E.C. Zwarthoff, Dan Theodorescu, James C. Costello, Jolien T. M. Mensink
Publikováno v:
Cancer Research. 81:615-615
Intravesical instillations with Bacillus Calmette-Guérin (BCG) is the recommended treatment for T1 high-grade (HG) bladder cancer (BC) patients. Unfortunately, risk stratification is insufficient to identify patients at risk of BCG treatment failure
Autor:
Vebjørn Kvikstad, Jolien T. M. Mensink, Deric K. Van der Schoot, Florus C. de Jong, Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff, Egbert R. Boevé, Robert F. Hoedemaeker
Publikováno v:
Clinical Cancer Research. 26:B06-B06
Introduction: High-risk non-muscle invasive bladder cancer (HR-NMIBC) patients represent a challenging group as they have the highest risk of treatment failure despite transurethral tumor resection (TUR) and adjuvant intravesical Bacillus Calmette-Gu